Abstract
Background: Podocyte damage and accumulation of advanced glycation end-products (AGEs) are implicated in the development and progression of diabetic nephropathy. We have previously shown that changes in podocyte pathophysiology, such as hypertrophy and reduced migration, are closely linked with the induction of the cell cycle inhibitor p27Kip1 and a decrease in neuropilin-1 (NRP1) expression. We investigated whether the erythropoietin receptor activators CERA and epoetin-β may prevent AGE-mediated changes in podocytes. Methods: Differentiated mouse podocytes in culture were challenged by AGE-modified bovine serum albumin (BSA) or control BSA in the presence or absence of CERA as well as epoetin-β. Cell cycle analysis and determination of apoptosis markers were performed. p27Kip1 and NRP1 expression was measured by RT-PCR and Western blots. Results: Differentiated mouse podocytes in culture expressed erythropoietin receptors which were phosphorylated after incubation with CERA or epoetin-β. CERA or epoetin-β prevented the p27Kip1-dependent cell cycle arrest and cellular hypertrophy induced by AGE-BSA incubation. Furthermore, the p27Kip1-dependent AGE-BSA-induced decrease in cell viability and decrease in cell proliferation was ameliorated in the presence of CERA or epoetin-β. Following erythropoietin treatment, AGE-BSA failed to further reduce NRP1 expression, resulting in improved podocyte migration. Conclusion: Treatment with the erythropoietin receptor activators epoetin-β or CERA protected podocytes from AGE-BSA-mediated damage via an effect on p27Kip1 and NRP1 expression. Consequently, early treatment with erythropoietin may help to prevent diabetic nephropathy.
Journal Section:
Original Paper
References
1.
Wolf G, Chen S, Ziyadeh FN: From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005;54:1626–1634.
[PubMed]
2.
White KE, Bilous RW, Marshall SM, El Nahas M, Remuzzi G, Piras G, de Cosmo S, Viberti G: Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 2002;51:3083–3089.
[PubMed]
3.
Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW: Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997;99:342–348.
[PubMed]
4.
Miyauchi M, Toyoda M, Kobayashi K, Abe M, Kobayashi T, Kato M, Yamamoto N, Kimura M, Umezono T, Suzuki D: Hypertrophy and loss of podocytes in diabetic nephropathy. Intern Med 2009;48:1615–1620.
[PubMed]
5.
Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, Saunders TL, Dysko RC, Kohno K, Holzman LB, Wiggins RC: Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005;16:2941–2952.
[PubMed]
6.
Bohlender JM, Franke S, Stein G, Wolf G: Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005;289:F645–F659.
[PubMed]
7.
D’Agati V, Yan SF, Ramasamy R, Schmidt AM: RAGE, glomerulosclerosis and proteinuria: roles in podocytes and endothelial cells. Trends Endocrinol Metab 2010;21:50–56.
[PubMed]
8.
Rüster C, Bondeva T, Franke S, Förster M, Wolf G: Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes. Nephrol Dial Transplant 2008;23:2179–2191.
[PubMed]
9.
Bondeva T, Rüster C, Franke S, Hammerschmid E, Klagsbrun M, Cohen CD, Wolf G: Advanced glycation end-products suppress neuropilin-1 expression in podocytes. Kidney Int 2009;75:605–616.
[PubMed]
10.
Bondeva T, Wolf G: Advanced glycation end products suppress neuropilin-1 expression in podocytes by a reduction in Sp1-dependent transcriptional activity. Am J Nephrol 2009;30:336–345.
[PubMed]
11.
Wolf G, Müller N, Hunger-Battefeld W, Kloos C, Müller UA: Hemoglobin concentrations are closely linked to renal function in patients with type 1 or 2 diabetes mellitus. Kidney Blood Press Res 2008;31:313–321.
[PubMed]
12.
Mehdi U, Toto RD: Anemia, diabetes, and chronic kidney disease. Diabetes Care 2009;32:1320–1326.
[PubMed]
13.
Vlagopoulos PT, Tighiouart H, Weiner DE, Griffith J, Pettitt D, Salem DN, Levey AS, Sarnak MJ: Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 2005;16:3403–3410.
[PubMed]
14.
Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shanfinfar S, Simpson RL, Snapinn SM, Toto R: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003;63:1499–1507.
[PubMed]
15.
Goldman SA, Nedergaard M: Erythropoietin strikes a new cord. Nat Med 2002;8:785–787.
[PubMed]
16.
Fliser D, Bahlmann FH, de Groot K, Haller H: Mechanisms of disease: erythropoietin – an old hormone with a new mission? Nat Clin Pract Cardiovasc Med 2006;3:563–572.
[PubMed]
17.
Schiffer M, Park JK, Tossidou I, Bartels J, Shushakova N, Menne J, Fliser D: Erythropoietin prevents diabetes-induced podocyte damage. Kidney Blood Press Res 2008;31:411–415.
[PubMed]
18.
Menne J, Park JK, Shushakova N, Mengel M, Meier M, Fliser D: The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury. J Am Soc Nephrol 2007;18:2046–2053.
[PubMed]
19.
Mundel P, Reiser J, Zúñiga Mejía Borja A, Pavenstädt H, Davidson GR, Kriz W, Zeller R: Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997;236:248–258.
[PubMed]
20.
Shankland SJ, Pippin JW, Reiser J, Mundel P: Podocytes in culture: past, present, and future. Kidney Int 2007;72:26–36.
[PubMed]
21.
Busch M, Franke S, Wolf G, Brandstädt A, Ott U, Gerth J, Hunsicker LG, Stein G: The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. Am J Kidney Dis 2006;48:571–579.
[PubMed]
22.
Wolf G, Schroeder R, Zahner G, Stahl RAK, Shankland SJ: High glucose-induced hypertrophy of mesangial cells requires p27Kip1, an inhibitor of cyclin-dependent kinases. Am J Pathol 2001;158:1091–1100.
[PubMed]
23.
Echigoya MH, Obikane K, Nakashima T, Sasaki S: Glomerular localization of erythropoietin receptor mRNA and protein in neonatal and mature mouse kidney. Nephron Exp Nephrol 2005;100:e21–e29.
[PubMed]
24.
Eto N, Wada T, Inagi R, Takano H, Shimizu A, Kato H, Kurihara H, Kawachi H, Shankland SJ, Fujita T, Nangaku M: Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int 2007;72:455–463.
[PubMed]
25.
Thomas MC, Forbes JM, Cooper ME: Advanced glycation end products and diabetic nephropathy. Am J Ther 2005;12:562–572.
[PubMed]
26.
Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D’Agati V, Schmidt AM: RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003;162:1123–1137.
[PubMed]
27.
Juul SE, Yachnis AT, Christensen RD: Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 1998;52:235–249.
[PubMed]
28.
Morakkabati N, Gollnick F, Meyer R, Fandrey J, Jelkmann W: Erythropoietin induces Ca2+ mobilization and contraction in rat mesangial and aortic smooth muscle cultures. Exp Hematol 1996;24:392–397.
[PubMed]
29.
Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas F, Tabira T, Sasaki R: Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 1993;268:11208–11216.
[PubMed]
30.
Logar CM, Brinkkoetter PT, Krofft RD, Pippin JW, Shankland SJ: Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int 2007;72:489–498.
[PubMed]
31.
Toba H, Sawai N, Morishita M, Murata S, Yoshida M, Nakashima K, Morita Y, Kobara M, Nakata T: Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat. Eur J Pharmacol 2009;612:106–114.
[PubMed]
32.
Bahlmann FH, Song R, Boehm SM, Mengel M, von Wasielewski R, Lindschau C, Kirsch T, de Groot K, Laudeley R, Niemczyk E, Güler F, Menne J, Haller H, Fliser D: Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004;110:1006–1012.
[PubMed]
33.
Bi B, Guo J, Marlier A, Lin SR, Cantley LG: Erythropoietin expands a stromal cell population that can mediate renoprotection. Am J Physiol Renal Physiol 2008;295:F1017–F1022.
[PubMed]
34.
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019–2032.
[PubMed]
© 2010 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2010
You do not currently have access to this content.
